scholarly journals Guillain-Barre syndrome in pregnancy- a rare entity

2020 ◽  
Vol 9 (11) ◽  
pp. 4734
Author(s):  
Snehal W. Pakhale ◽  
Angela Sehra ◽  
Seema Bhardwaj
Keyword(s):  
Cesarean Section ◽  
Autoimmune Disorder ◽  
Guillain Barre Syndrome ◽  
Thromboembolism Prophylaxis ◽  
Residual Symptoms ◽  
Emergency Cesarean ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Brain And Spinal Cord ◽  
Progressive Weakness

Guillain-Barre syndrome (GBS) is a rare, autoimmune disorder. Estimated incidence is 0.62 to 2.66 cases per 100000 people annually. We report a case of GBS in 29 years old primigravida with pre-gestational diabetes mellitus controlled on insulin, who presented at 7 weeks of the period of gestation with complaints of numbness in both hands and fingers. After 3 days of hospital admission, she had progressive weakness in both limbs and difficulty in walking. MRI of the brain and spinal cord done to exclude other possible causes and was normal. All the other blood investigations including electrolytes were normal. Nerve conduction velocity test was suggestive of acute inflammatory demyelinating axonal motor polyneuropathy and diagnosis of GBS was made. She was managed by multidisciplinary approach in intensive care unit. The patient improved after plasmapheresis and supportive measures as thromboembolism prophylaxis and physiotherapy. Patient was discharged after 2 weeks of hospital stay and had no residual symptoms after 1 month. She was readmitted at 32 weeks of gestation with severe preeclampsia and underwent emergency cesarean section delivering 1.9 kg male baby. She was discharged on day 4 of cesarean section and followed in postpartum period for complications. To summarize, GBS can appear at any stage of pregnancy & postpartum. Diagnosis can be delayed, so needs high index of clinical suspicion. Early diagnosis along with prompt intensive multidisciplinary supportive care improves outcomes for the mother and foetus.  

scholarly journals A CASE REPORT ON GUILLAIN BARRE SYNDROME (G B SYNDROME) IN CHILD – AN SUCCESSFUL APPROACH IN AYURVEDA

2020 ◽  
Vol 8 (9) ◽  
pp. 4556-4559
Author(s):  
Shruti K Kamath ◽  
Vinay Kumar K N
Keyword(s):  
Case Report ◽  
Autoimmune Disorder ◽  
The Elderly ◽  
Bimodal Distribution ◽  
Epidemiological Studies ◽  
Guillain Barre Syndrome ◽  
Common Symptom ◽  
Guillain Barré Syndrome ◽  
Successful Approach ◽  
Guillain Barré

Guillain Barre Syndrome is an autoimmune disorder encompassing a heterogeneous group of pathological and clinical entities. Antecedent infections are thought to trigger an immune response which subsequently cross reacts with nerves leading to demyelination or axonal degeneration. The condition can occur at any age. One of the earliest descriptions of what we know today as guillian barre syndrome is found in Land-ry’s report on 10 Patients with “ascending paralysis” in 1859. The annual incidence of G B Syndrome is around 1-3/100000 population according to epidemiological studies from Europe, USA and Australia. The age specific curve seems to show a bimodal distribution with peaks in young adults and the elderly. The risk of G B Syndrome is lower during pregnancy and increases after delivery. However, it can occur to children as well which is the common cause of acute flaccid paralysis (AFP) wherein the clinical features are acute paralysis evolving over days or weeks with loss of tendon reflexes. Pain is the most common symptom experienced by the patients. Here is a case report on a child aged 2 and half years suffering from G B syndrome who underwent Panchakarma treatment in Ayurveda under 2 phases that include Sarvanga Abhyanga, Sarvanga Shastika Shali Pinda Sweda, Dhanyamla Dhara, Agnilepa, Rajayapana Basti along with Physiotherapy and there were significant results observed.

scholarly journals Chronic recurrent Guillain-Barré syndrome: report of 3 cases

1989 ◽  
Vol 47 (1) ◽  
pp. 84-90 ◽  
Author(s):  
Antônio Rodrigues de Mello ◽  
Marcos R. G. de Freitas ◽  
Leila Chimelli
Keyword(s):  
Peripheral Nerves ◽  
Complete Recovery ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Progressive Weakness ◽  
Clinical And Pathological Features ◽  
Tendon Reflexes ◽  
Hypertrophic Changes ◽  
Syndrome Report

The classical Guillain-Barre syndrome is an acute or subacute polyradiculoneuropathy whose main clinical features are progressive weakness of the limbs, decrease or absence of tendon reflexes, and sensory changes. Although in most of the cases there is complete recovery in weeks or months, some patients have a slow and progressive relapsing course and present thickening of the peripheral nerves. In this paper we describe three cases of the chronic and relapsing variety of Guillain-Barré syndrome, two of which had prominent hypertrophic changes in the peripheral nerves with onion bulb formations The clinical and pathological features of this disease are reviewed. The three patients improved with the use of steroids.

scholarly journals Clinical factors associated with Guillain-Barré syndrome following surgery

2018 ◽  
Vol 8 (3) ◽  
pp. 201-206 ◽  
Author(s):  
Sara Hocker ◽  
Elanagan Nagarajan ◽  
Mark Rubin ◽  
Eelco F.M. Wijdicks
Keyword(s):  
Conscious Sedation ◽  
Univariate Analysis ◽  
Autoimmune Disorder ◽  
Guillain Barre Syndrome ◽  
Factors Associated ◽  
Guillain Barré Syndrome ◽  
Autoimmune Conditions ◽  
Clinical Associations ◽  
Guillain Barré ◽  
A Prospective Study

BackgroundWe sought to identify clinical associations and potential triggers of Guillain-Barré syndrome (GBS) within 6 weeks of surgery.MethodsWe retrospectively reviewed consecutive patients diagnosed with GBS within 6 weeks of a surgery between January 1995 and June 2014 at Mayo Clinic. Postsurgical GBS was defined as symptom onset within 6 weeks of surgery. Patients with postsurgical GBS were compared with patients who did not have a surgery prior to GBS onset to determine differences between groups.ResultsA total of 208 patients with GBS, median age 55 years (interquartile range [IQR] 41–68), were included. Nineteen patients (9.1%) developed postsurgical GBS. Median duration from the surgery to onset of first GBS symptom was 15 days (IQR 9–37). The main types of surgeries preceding GBS were gastrointestinal, orthopedic, and cardiac. General anesthesia was used in 18 (95%) and conscious sedation in 1 (5%) patient. Among the 19 patients with postsurgical GBS, 11 (57.9%) had a known diagnosis of malignancy. Autoimmune conditions were present in 5 (26.3%) patients. Postoperative infection was found in 4 (21%) patients. On univariate analysis, the factors that showed an association with postsurgical GBS were age (p = 0.02), malignancy (p ≤ 0.0004), active malignancy (p = 0.03), preexisting autoimmune disorder (p = 0.02), and infection (p = 0.0001). On multivariate analysis, only active malignancy (0.03) remained associated.ConclusionsSurgery antedated GBS in 9.1% of patients. Postsurgical GBS was more common in patients with an active malignancy. A prospective study is needed to determine whether active malignancy represents an independent risk factor for the development of postsurgical GBS.

scholarly journals Guillain-Barré syndrome associated with COVID- 19 vaccination: a case report

2021 ◽  
Vol 10 (1) ◽  
pp. 268
Author(s):  
Vinod John ◽  
Jiya Thankam Koshy ◽  
Nikhil Gladson ◽  
Vimod K. Wills
Keyword(s):  
Adverse Effect ◽  
Acute Onset ◽  
Lower Limbs ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
History Of ◽  
Guillain Barré ◽  
Progressive Weakness ◽  
Relevant Factors

Several reports and studies are being conducted to this day based on the safety profile of COVID-19 vaccines. COVID-19 vaccination inducing GBS is a rare adverse effect and is likely to be causal. Though, there are reports concerning the relation between coronavirus infections and GBS, the pathogenic mechanism and relevant factors behind COVID-19 vaccines inducing GBS are still not being corroborated so far. Guillain-Barre syndrome is the principal cause of acute flaccid paralysis with a prevalence rate of 2 in 100, 000 people per year. We illustrate a 55 years old female patient who presented with acute onset paraesthesia and progressive weakness of bilateral lower limbs and gait imbalance of 5 days duration to the Hospital during the first week of September. Her symptoms occurred within 2 weeks of the first dose of the ChAdOx1-n-CoV-19 (Covishield) vaccine proving a major possibility of vaccine-induced neurological adverse effect as she didn't have any likely significant history of illness or allergies in the past rather than type 2 diabetes mellitus. This report aims to highlight the incidence and to ruminate upon this matter while evaluating any GBS cases in the current eras of the COVID-19 pandemic and vaccination.

scholarly journals Guillain-Barre Syndrome: an autoimmune disorder post-COVID1-9 vaccination?

2021 ◽  
Author(s):  
Zafran Khan ◽  
Ubaid Ahmad ◽  
Daniya Ualiyeva ◽  
Obed Boadi Amissah ◽  
Asaf Khan ◽  
...  
Keyword(s):  
Autoimmune Disorder ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Anesthesia for Cesarean Section in a Patient with Guillain-Barre Syndrome: Case Report

2013 ◽  
Vol 63 (4) ◽  
pp. 369-371 ◽  
Author(s):  
Daniel Volquind ◽  
Roberto Taboada Fellini ◽  
Giana Lucho Rose ◽  
Gabriel Pedro Tarso
Keyword(s):  
Case Report ◽  
Cesarean Section ◽  
Guillain Barre Syndrome ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

scholarly journals Health burden in the Netherlands due to infection with thermophilic Campylobacter spp.

2000 ◽  
Vol 125 (3) ◽  
pp. 505-522 ◽  
Author(s):  
A. H. HAVELAAR ◽  
M. A. S. de WIT ◽  
R. van KONINGSVELD ◽  
E. van KEMPEN
Keyword(s):  
Acute Gastroenteritis ◽  
Severity Of Illness ◽  
Premature Mortality ◽  
Guillain Barre Syndrome ◽  
Years Of Life Lost ◽  
Residual Symptoms ◽  
Health Burden ◽  
Guillain Barré Syndrome ◽  
Main Determinants ◽  
Guillain Barré

Infection with thermophilic Campylobacter spp. usually leads to an episode of acute gastroenteritis. Occasionally, more severe diseases may be induced, notably Guillain–Barré syndrome and reactive arthritis. For some, the disease may be fatal. We have integrated available data in one public health measure, the Disability Adjusted Life Year (DALY). DALYs are the sum of Years of Life Lost by premature mortality and Years Lived with Disability, weighted with a factor between 0 and 1 for the severity of illness. The mean health burden of campylobacter-associated illness in the Dutch population in the period 1990–5 is estimated as 1400 (90% CI 900–2000) DALY per year. The main determinants of health burden are acute gastroenteritis (440 DALY), gastroenteritis related mortality (310 DALY) and residual symptoms of Guillain–Barré syndrome (340 DALY). Sensitivity analysis demonstrated that alternative model assumptions produced results in the above-mentioned range.

scholarly journals Intravenous immunoglobulin treatment for mild Guillain-Barré syndrome: an international observational study

2021 ◽  
pp. jnnp-2020-325815
Author(s):  
Christine Verboon ◽  
Thomas Harbo ◽  
David R Cornblath ◽  
Richard A C Hughes ◽  
Pieter A van Doorn ◽  
...  
Keyword(s):  
Supportive Care ◽  
Intravenous Immunoglobulin ◽  
Guillain Barre Syndrome ◽  
Study Entry ◽  
Ivig Treatment ◽  
Disease Course ◽  
Disability Score ◽  
Residual Symptoms ◽  
Guillain Barré Syndrome ◽  
Guillain Barré

ObjectiveTo compare the disease course in patients with mild Guillain-Barré syndrome (GBS) who were treated with intravenous immunoglobulin (IVIg) or supportive care only.MethodsWe selected patients from the prospective observational International GBS Outcome Study (IGOS) who were able to walk independently at study entry (mild GBS), treated with one IVIg course or supportive care. The primary endpoint was the GBS disability score four weeks after study entry, assessed by multivariable ordinal regression analysis.ResultsOf 188 eligible patients, 148 (79%) were treated with IVIg and 40 (21%) with supportive care. The IVIg group was more disabled at baseline. IVIg treatment was not associated with lower GBS disability scores at 4 weeks (adjusted OR (aOR) 1.62, 95% CI 0.63 to 4.13). Nearly all secondary endpoints showed no benefit from IVIg, although the time to regain full muscle strength was shorter (28 vs 56 days, p=0.03) and reported pain at 26 weeks was lower (n=26/121, 22% vs n=12/30, 40%, p=0.04) in the IVIg treated patients. In the subanalysis with persistent mild GBS in the first 2 weeks, the aOR for a lower GBS disability score at 4 weeks was 2.32 (95% CI 0.76 to 7.13). At 1 year, 40% of all patients had residual symptoms.ConclusionIn patients with mild GBS, one course of IVIg did not improve the overall disease course. The certainty of this conclusion is limited by confounding factors, selection bias and wide confidence limits. Residual symptoms were often present after one year, indicating the need for better treatments in mild GBS.

scholarly journals Case of Guillain-Barré syndrome following COVID-19 vaccine

2021 ◽  
Vol 14 (6) ◽  
pp. e243629
Author(s):  
Tanveer Hasan ◽  
Mustafizur Khan ◽  
Farhin Khan ◽  
Ghanim Hamza
Keyword(s):  
Peripheral Nerves ◽  
Lower Limbs ◽  
Guillain Barre Syndrome ◽  
Intramuscular Dose ◽  
Immune Mediated ◽  
Guillain Barré Syndrome ◽  
History Of ◽  
Guillain Barré ◽  
Tract Infections ◽  
Progressive Weakness

Guillain-Barré syndrome (GBS) is a rare immune-mediated disorder of the peripheral nerves. Although its cause is not fully understood, the syndrome often follows infection with a virus or bacteria, although in rare occasions, vaccination may precede GBS. We describe a case of a 62-year-old woman who presented with paraesthesia and progressive weakness of both lower limbs over 3 days. Clinical examination and investigation findings including lumbar puncture and nerve conduction studies were consistent with the diagnosis of GBS. She had no history of either diarrhoea or respiratory tract infections preceding her presentation. However, she had her first intramuscular dose of the Oxford/AstraZeneca COVID-19 vaccine 11 days prior to her presentation. Although no direct link could be ascertained, the purpose of this report is to highlight the incidence and consider this issue while evaluating any case of GBS in the light of the current pandemic and vaccination programme.

scholarly journals Guillain-Barré Syndrome: A Rare Case Report

2021 ◽  
pp. 263-267
Author(s):  
Roshani Dhanvijay ◽  
Ruchira Ankar
Keyword(s):  
Spinal Cord ◽  
The United States ◽  
The Body ◽  
Guillain Barre Syndrome ◽  
Bladder Control ◽  
Guillain Barré Syndrome ◽  
Guillain Barré ◽  
Hands And Feet ◽  
Brain And Spinal Cord ◽  
The Brain

Introduction: Guillain-Barré syndrome (GBS) is a rare neurodegenerative condition in which the immune system of the body mistakenly damages a portion of the peripheral nerve system. The initial signs are general weakness and numbness in the limbs. Initial symptoms occur within a few days or weeks of infection. These symptoms can spread fast, ultimately paralyzing the entire body. The peripheral system consists of the brain and spinal cord.  The nerve network is found outside of the brain and spinal cord. GBS can range from a minor case with short weakness to a completely fatal paralysis that renders the individual unable to breathe on their own. Fortunately, even the most severe instances of GBS may be recovered from. Some people will remain feeble even after they have recovered. The majority of patients reach the peak of their weakness within the first two weeks of symptoms appearing; by the third week, 90 percent of those affected are at their weakest. Symptoms of muscle weakness include difficulty with muscles of the eyes and vision, swallowing difficulties, difficulty in speaking, or chewing, pricking or pins and needles sensations in the hands and feet, pain that can be severe, especially at night, coordination problems, and unsteadiness, abnormal heartbeat/rate or blood pressure, problems with digestion and/or bladder control, and problems with digestion and/or bladder control. Background: Guillain-Barré syndrome can affect anyone. It can attack at any age (though it is more common in adults and the elderly), and both sexes are equally susceptible to the condition. GBS is predicted to afflict one in every 100,000 people each year. GBS affects between 3,000 and 6,000 persons in the United States each year. Case Presentation: A 53 years old male patient came to the hospital with the chief complaint of weakness in all four limbs for 6 days. A patient was apparently alright 6 days back later he was experience weakness in the left side of the body following covid vaccination on 4th June, weakness was gradually progressive in nature and progress to the right side of the body after 2 days. Later on, 8th of June patient got admitted to GMC yavatmal where the routine investigation was done including a CT scan brain which normal and doctors ask for an MRI brain for which the patient and his relative had taken a DAMA discharge and brought the patient to AVBR Hospital. All investigation has been done after that the physician diagnosed the patient having Guillain barre syndrome. The patient weakness has been worse and the treatment start according to the disease condition. Medical treatment including physical therapy also been started to reducing physical weakness and the patient condition is improved day by day. Intervention: The intervention was given to the patient such as injection ceftriaxone 1 gm BD, Inj pan 40 mg OD, Inj Emset 4 mg  TDS, Inj optinurone 1 Amp in 100 ml normal saline.

Sign in / Sign up

Export Citation Format

Share Document